Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Brief Summary: The purpose of this study is to assess whether co-administration of belimumab and a single cycle of rituximab will optimize treatment with belimumab, which will result in improvements of clinical status with a favorable safety profile, by comparing subjects randomized to belimumab plus rituximab versus belimumab plus rituximab-placebo. Approximately 292 subjects will be randomized in a 1:2:1 ratio to 1 of 3 treatment arms; belimumab plus rituximab-placebo (Arm A, control), belimumab plus rituximab (Arm B, combination), or belimumab plus standard therapy (Arm C, reference). Belimumab will be administered as subcutaneous (SC) and rituximab-placebo or rituximab will be administered by intravenous (IV) infusions. The total duration of the study is for 104 weeks.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Belimumab 4 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Beimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Belimumab 20 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 4 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Beimumab 10 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 20 mg/kg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Belimumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Belimumab, Drug: Rituximab-placebo, Drug: Standard therapy (Excluding Immunosuppressants), Drug: Steroid Taper | Arm Label: Belimumab + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Belimumab, Drug: Rituximab, Drug: Standard therapy (Excluding Immunosuppressants), Drug: Steroid Taper | Arm Label: Belimumab + Standard therapy; Type: OTHER; Interventions: Drug: Belimumab, Drug: Standard therapy (Including Immunosuppressants), Drug: Steroid Taper | Intervention Type: DRUG; Name: Belimumab; Assigned to Arm(s): Belimumab + Placebo, Belimumab + Rituximab, Belimumab + Standard therapy | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Belimumab + Rituximab | Intervention Type: DRUG; Name: Rituximab-placebo; Assigned to Arm(s): Belimumab + Placebo | Intervention Type: DRUG; Name: Standard therapy (Including Immunosuppressants); Assigned to Arm(s): Belimumab + Standard therapy | Intervention Type: DRUG; Name: Standard therapy (Excluding Immunosuppressants); Assigned to Arm(s): Belimumab + Placebo, Belimumab + Rituximab | Intervention Type: DRUG; Name: Steroid Taper; Assigned to Arm(s): Belimumab + Placebo, Belimumab + Rituximab, Belimumab + Standard therapy
C: Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 10 mg/kg | Intervention Type: BIOLOGICAL; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: BIOLOGICAL; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg
D: Arm Label: Placebo plus SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 4 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 4 mg/kg | Arm Label: Belimumab 10 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus SOC | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 4 mg/kg; Assigned to Arm(s): Belimumab 4 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus SOC

Answer: B